
Shares of drug developer Anika Therapeutics ANIK.O fall 2.7% to $16.54 in afternoon trade
Company says it completes planned divestiture of its Parcus Medical business to Medacta Group MOVE.S to focus on its core hyaluronic acid technology for osteoarthritis pain management and expand its regenerative solutions portfolio
Anika says the sale was completed with total cash consideration received at closing for an undisclosed amount
Company reported its plan to divest Parcus Medical in October 2024
ANIK down 34.7% in the past 12 months